Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
David Lang,1,2 Wolfgang Haslinger,2 Kaveh Akbari,2,3 Mario Scala,2,3 Benedikt Hergan,2,3 Christian Asel,2,3 Andreas Horner,1,2 Romana Wass,1,2 Elmar Brehm,1,2 Bernhard Kaiser,1 Bernd Lamprecht1,2 1Johannes Kepler University Hospital, Department of Pulmonology, Linz, Austria; 2Johannes Kepler Univers...
Enregistré dans:
Auteurs principaux: | Lang D, Haslinger W, Akbari K, Scala M, Hergan B, Asel C, Horner A, Wass R, Brehm E, Kaiser B, Lamprecht B |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/de62df45ecee46c7bf7642e198ce9c9e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
par: Selina K. Wong, et autres
Publié: (2021) -
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
par: Anwen Xiong, et autres
Publié: (2021) -
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
par: Zoe Apalla, et autres
Publié: (2021) -
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
par: Xiaozhun Huang, et autres
Publié: (2021) -
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
par: Elena A. Demina
Publié: (2021)